381 related articles for article (PubMed ID: 19275756)
1. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.
Bedard PL; de Azambuja E; Cardoso F
Curr Cancer Drug Targets; 2009 Mar; 9(2):148-62. PubMed ID: 19275756
[TBL] [Abstract][Full Text] [Related]
2. HER-2 signaling and inhibition in breast cancer.
Browne BC; O'Brien N; Duffy MJ; Crown J; O'Donovan N
Curr Cancer Drug Targets; 2009 May; 9(3):419-38. PubMed ID: 19442060
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
4. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
5. HER-2-positive breast cancer: hope beyond trastuzumab.
Bartsch R; Wenzel C; Zielinski CC; Steger GG
BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
[TBL] [Abstract][Full Text] [Related]
6. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
7. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
Huang Y; Fu P; Fan W
Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
[TBL] [Abstract][Full Text] [Related]
8. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
9. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
11. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer.
Lesniak D; Xu Y; Deschenes J; Lai R; Thoms J; Murray D; Gosh S; Mackey JR; Sabri S; Abdulkarim B
Cancer Res; 2009 Nov; 69(22):8620-8. PubMed ID: 19887601
[TBL] [Abstract][Full Text] [Related]
12. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
13. Resistance to human epidermal growth factor receptor type 2-targeted therapies.
Thery JC; Spano JP; Azria D; Raymond E; Penault Llorca F
Eur J Cancer; 2014 Mar; 50(5):892-901. PubMed ID: 24462377
[TBL] [Abstract][Full Text] [Related]
14. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
[TBL] [Abstract][Full Text] [Related]
15. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
16. Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Flaherty KT; Brose MS
Curr Oncol Rep; 2006 Mar; 8(2):90-5. PubMed ID: 16507217
[TBL] [Abstract][Full Text] [Related]
17. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB; Garrett JT; Estrada MV; Moore PD; Ericsson PG; Koch JP; Langley E; Singh S; Kim PS; Frampton GM; Sanford E; Owens P; Becker J; Groseclose MR; Castellino S; Joensuu H; Huober J; Brase JC; Majjaj S; Brohée S; Venet D; Brown D; Baselga J; Piccart M; Sotiriou C; Arteaga CL
Clin Cancer Res; 2017 Aug; 23(15):4323-4334. PubMed ID: 28381415
[No Abstract] [Full Text] [Related]
18. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?
Widakowich C; Dinh P; de Azambuja E; Awada A; Piccart-Gebhart M
Anticancer Agents Med Chem; 2008 Jun; 8(5):488-96. PubMed ID: 18537532
[TBL] [Abstract][Full Text] [Related]
19. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer.
Wong H; Leung R; Kwong A; Chiu J; Liang R; Swanton C; Yau T
Oncologist; 2011; 16(11):1535-46. PubMed ID: 22020213
[TBL] [Abstract][Full Text] [Related]
20. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]